Clinicopathologic Features and Response to Therapy of NRG1 Fusion–Driven Lung Cancers: The eNRGy1 Global Multicenter Registry

Drilon A.Duruisseaux M.Han J.-Y.Ito M.Falcon C.Yang S.-R.Murciano-Goroff Y.R.Chen H.Okada M.Molina M.A.Wislez M.Brun P.Dupont C.Branden E.Rossi G.Schrock A.Ali S.Gounant V.Magne F.Blum T.G.Schram A.M.Monnet I.JIN-YUAN SHIHSabari J.Pérol M.Zhu V.W.Nagasaka M.Doebele R.Camidge D.R.Arcila M.Ou S.-H.I.Moro-Sibilot D.Rosell R.Muscarella L.A.Liu S.V.Cadranel J.2021-11-032021-11-0320211527-7755https://www.scopus.com/inward/record.uri?eid=2-s2.0-85108078188&doi=10.1200%2fJCO.20.03307&partnerID=40&md5=6ea7d0ffbf8c8dabcadfb57377eb3928https://scholars.lib.ntu.edu.tw/handle/123456789/586131PURPOSE: Although NRG1 fusions are oncogenic drivers across multiple tumor types including lung cancers, these are difficult to study because of their rarity. The global eNRGy1 registry was thus established to characterize NRG1 fusion-positive lung cancer[SDGs]SDG3antineoplastic agent; neu differentiation factor; NRG1 protein, human; oncoprotein; tumor marker; adult; aged; Asia; clinical trial; Europe; female; follow up; genetics; human; immunology; immunotherapy; lung tumor; male; middle aged; mortality; multicentClinicopathologic Features and Response to Therapy of NRG1 Fusion–Driven Lung Cancers: The eNRGy1 Global Multicenter Registryjournal article10.1200/JCO.20.03307340772682-s2.0-85108078188